Relay Therapeutics, Inc.
Clinical trials sponsored by Relay Therapeutics, Inc., explained in plain language.
-
New drug targets root cause of rare overgrowth diseases in kids and adults
Disease control Recruiting nowThis study tests a new drug, RLY-2608, designed to block a faulty protein that causes abnormal growth in people with PIK3CA-related overgrowth spectrum (PROS) and related malformations. The trial enrolls 277 adults and children to see if the drug can safely shrink overgrown tissu…
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for hard-to-treat breast cancer: targeted combo enters phase 3
Disease control Recruiting nowThis study tests whether a new drug (RLY-2608) combined with fulvestrant works better than another approved combination (capivasertib + fulvestrant) for people with advanced or metastatic HR+/HER2- breast cancer that has a PIK3CA mutation. About 540 adults whose cancer worsened a…
Phase: PHASE3 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New drug targets Hard-to-Treat cancers with specific gene mutation
Disease control Recruiting nowThis early-stage study tests a new drug, RLY-2608, designed to block a faulty protein in cancer cells with a specific gene change (PIK3CA mutation). It is for adults with advanced solid tumors or certain breast cancers that have not responded to other treatments. The study will t…
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 04, 2026 16:20 UTC